← back to search

Gregory S. Day

Jacksonville College · US
Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Autoimmune Neurological Disorders and Treatments, and Functional Brain Connectivity Studies.
h-index
40
citations
8,382
works
386
NIH funding
primary concept
email

Recent publications

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
The Lancet Neurology 2025cited by 34position: middledoi
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Nature Medicine 2025cited by 21position: middledoi
Depressive Symptoms and Amyloid Pathology
JAMA Psychiatry 2025cited by 19position: middledoi
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Alzheimer s Research & Therapy 2025cited by 13position: middledoi
The Clinical Trial Landscape in Autoimmune Encephalitis
Neurology 2025cited by 12position: middledoi
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Brain 2025cited by 12position: middledoi
An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote
Journal of Neuroimmunology 2025cited by 8position: middledoi
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Nature Aging 2025cited by 8position: middledoi
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Brain 2025cited by 6position: middledoi
The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysis
The Lancet Psychiatry 2025cited by 6position: middledoi
Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials
The Journal of Prevention of Alzheimer s Disease 2025cited by 5position: middledoi
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
Alzheimer s & Dementia 2025cited by 3position: middledoi
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease
The Journal of Prevention of Alzheimer s Disease 2025cited by 2position: middledoi
Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias
npj Dementia 2025cited by 2position: middledoi
Magnetic Resonance Imaging Characteristics of LGI1-Antibody and CASPR2-Antibody Encephalitis
JAMA Neurology 2024cited by 37position: middledoi
PNMA2 forms immunogenic non-enveloped virus-like capsids associated with paraneoplastic neurological syndrome
Cell 2024cited by 34position: middledoi
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
JAMA Neurology 2024cited by 27position: middledoi
Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease
Nature Communications 2024cited by 22position: middledoi
Trends in management of patients with new‐onset refractory status epilepticus (<scp>NORSE</scp>) from 2016 to 2023: An interim analysis
Epilepsia 2024cited by 20position: middledoi
Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Epilepsia 2024cited by 18position: middledoi
Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Alzheimer s & Dementia 2024cited by 17position: middledoi
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease
medRxiv 2024cited by 0position: middledoi
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
Nature Medicine 2023cited by 168position: middledoi
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
JAMA Neurology 2023cited by 84position: middledoi
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Alzheimer s & Dementia 2023cited by 79position: middledoi
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Nature Neuroscience 2023cited by 45position: middledoi
The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort
Alzheimer s & Dementia 2023cited by 38position: middledoi
Sex and <i>APOE ε4</i> carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Alzheimer s & Dementia 2023cited by 29position: middledoi
Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Alzheimer s & Dementia 2023cited by 24position: middledoi
Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
Alzheimer s & Dementia 2023cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Stacey Clardy · University of Utah5 papers (2021–2025)Divyanshu Dubey · Southwestern Medical Center3 papers (2022–2025)Sarosh R. Irani · Jacksonville College3 papers (2022–2025)Maarten J. Titulaer · Erasmus MC3 papers (2021–2025)Stefanie Rodenbeck · University of Utah2 papers (2021–2022)Tammy Smith · University of Utah2 papers (2024–2025)Αναστασία Ζεκερίδου · University of Lausanne2 papers (2022–2025)A. Sebastian López‐Chiriboga · Mayo Clinic2 papers (2022–2024)Eoin P. Flanagan · Mayo Clinic2 papers (2022–2024)Jeffrey M. Gelfand · DJO Global (Germany)2 papers (2022–2025) · 2 papers (2022–2024)Amanda L. Piquet · University of Colorado Anschutz Medical Campus1 papers (2024–2024)Lahiru Handunnetthi · Centre for Human Genetics1 papers (2024–2024) · 1 papers (2022–2022)Justin Abbatemarco · Cleveland Clinic1 papers (2021–2021)Nicolas R. Barthélemy · Washington Center1 papers (2022–2022)Michael P. Hantak · University of Utah1 papers (2024–2024) · 1 papers (2024–2024)Cédric Feschotte · Inserm1 papers (2024–2024)Ross W. Paterson · University of San Francisco1 papers (2022–2022)